Corvus Pharmaceuticals CRVS Fair Value Adjustment Of Warrants
Fair Value Adjustment Of Warrants at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The official record: Corvus Pharmaceuticals’s 10-Q, filed August 7, 2025, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's fair value adjustment of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's fair value adjustment of warrants?
- Corvus Pharmaceuticals (CRVS) reported fair value adjustment of warrants of -$2.01M in Q2 2025.
- How has Corvus Pharmaceuticals's fair value adjustment of warrants changed year-over-year?
- Corvus Pharmaceuticals's fair value adjustment of warrants decreased by 10.8% year-over-year, from -$1.82M to -$2.01M.
- What does fair value adjustment of warrants mean?
- This reflects the non-cash gain or loss recognized due to changes in the fair value of outstanding warrant liabilities that are classified as financial instruments. Because these warrants are marked-to-market, fluctuations in the company's stock price or volatility assumptions directly impact the reported net income. It is a critical adjustment for investors to isolate operational performance from accounting volatility related to derivative instruments.